Group 1 - Company atai Life Sciences is a clinical-stage biopharmaceutical firm focused on developing effective mental health treatments to improve patient outcomes [1][3] - The company has a pipeline of psychedelic-based therapies, including BPL-003 for treatment-resistant depression (TRD), VLS-01 for TRD, and EMP-01 for social anxiety disorder, all currently in Phase 2 clinical development [3] - atai is also working on a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD, aiming to provide scalable interventional psychiatry therapies [3] Group 2 - atai Life Sciences will participate in several investor conferences in September, including the Cantor Global Healthcare Conference on September 5, H.C. Wainwright Annual Global Investment Conference on September 8, and TD Cowen Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit on September 17 [1][2] - The format for these conferences will be fireside chats, and webcasts will be available on the company's website [2]

Shares of atai Life Sciences N.V. (ATAI) have been struggling lately and have lost 6.1% over the past week. However, a hammer chart pattern was formed in its last trading session, which could mean that the stock found support with bulls being able to counteract the bears. So, it could witness a trend reversal down the road. While the formation of a hammer pattern is a technical indication of nearing a bottom with potential exhaustion of selling pressure, rising optimism among Wall Street analysts about the ...

PART I. FINANCIAL INFORMATION [Financial Statements](index=3&type=section&id=Item%201.%20Financial%20Statements) This section presents unaudited condensed consolidated financial statements, including balance sheets, statements of operations, and cash flows, highlighting a net loss of $27.7 million for Q2 2025 and total assets of $189.2 million [Condensed Consolidated Balance Sheets](index=6&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) | Financial Metric | June 30, 2025 ($ thousands) | December 31, 2024 ($ thousands) | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | 61,940 | 17,505 | | Total current assets | 102,681 | 80,125 | | **Total assets** | **189,204** | **159,387** | | **Liabilities & Equity** | | | | Total current liabilities | 25,547 | 24,951 | | **Total liabilities** | **45,279** | **42,833** | | **Total stockholders' equity** | **143,925** | **116,554** | [Condensed Consolidated Statements of Operations](index=7&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) | Metric ($ thousands, except per share) | Q2 2025 | Q2 2024 | H1 2025 | H1 2024 | | :--- | :--- | :--- | :--- | :--- | | Total revenue | 719 | 273 | 2,274 | 273 | | Research and development | 11,092 | 12,605 | 22,420 | 24,136 | | General and administrative | 14,900 | 13,397 | 25,497 | 25,952 | | Loss from operations | (25,273) | (25,729) | (45,643) | (49,815) | | Net loss attributable to ATAI | (27,729) | (57,312) | (54,160) | (84,025) | | Net loss per share — basic and diluted | (0.14) | (0.36) | (0.29) | (0.53) | [Condensed Consolidated Statements of Cash Flows](index=10&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) | Cash Flow Activity ($ thousands) | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :--- | :--- | :--- | | Net cash used in operating activities | (31,935) | (38,801) | | Net cash provided by (used in) investing activities | (1,230) | 27,772 | | Net cash provided by financing activities | 67,362 | 326 | [Notes to Condensed Consolidated Financial Statements](index=11&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) - In June 2025, the company entered into a share purchase agreement to acquire the entire issued share capital of Beckley Psytech Limited not already owned. The transaction is expected to close in Q4 2025[37](index=37&type=chunk) - As of June 30, 2025, the company had cash and cash equivalents of **$61.9 million** and short-term securities of **$34.0 million**, which are expected to be sufficient to fund operations for at least the next 12 months[40](index=40&type=chunk)[41](index=41&type=chunk) - In February 2025, the company raised net proceeds of approximately **$59.1 million** from a public offering of common shares. In June 2025, it raised aggregate gross proceeds of approximately **$29.9 million** through a PIPE financing of common shares and pre-funded warrants[215](index=215&type=chunk)[216](index=216&type=chunk) - In May 2025, the company voluntarily prepaid and terminated its Hercules Loan Agreement, paying off the outstanding **$21.8 million** and recognizing a **$1.3 million** loss on extinguishment of debt[209](index=209&type=chunk) - The company invested approximately **$5.0 million** in Bitcoin in February 2025 as part of its treasury reserve diversification strategy[186](index=186&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=67&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses financial condition and operations, covering business overview, pipeline progress, strategic initiatives, and comparative financial results for Q2 and H1 2025 versus 2024 [Business Overview](index=67&type=section&id=Business%20Overview) - atai is a clinical-stage biopharmaceutical company focused on developing effective mental health treatments, with a pipeline of psychedelic and non-psychedelic product candidates[293](index=293&type=chunk)[295](index=295&type=chunk) - Key strategic initiatives include the pending acquisition of Beckley Psytech, expected to close in Q4 2025, and a planned corporate redomiciliation from the Netherlands to Delaware[302](index=302&type=chunk)[303](index=303&type=chunk) - The company is prioritizing clinical-phase programs with near-term data readouts, including BPL-003 for TRD, VLS-01 for TRD, and EMP-01 for Social Anxiety Disorder[306](index=306&type=chunk)[309](index=309&type=chunk) [Results of Operations](index=78&type=section&id=Results%20of%20Operations) | Metric ($ thousands) | Q2 2025 | Q2 2024 | Change (%) | | :--- | :--- | :--- | :--- | | Total revenue | 719 | 273 | 163% | | Research and development | 11,092 | 12,605 | (12%) | | General and administrative | 14,900 | 13,397 | 11% | | Loss from operations | (25,273) | (25,729) | (2%) | | Net loss | (27,746) | (57,369) | (52%) | | Metric ($ thousands) | H1 2025 | H1 2024 | Change (%) | | :--- | :--- | :--- | :--- | | Total revenue | 2,274 | 273 | 733% | | Research and development | 22,420 | 24,136 | (7%) | | General and administrative | 25,497 | 25,952 | (2%) | | Loss from operations | (45,643) | (49,815) | (8%) | | Net loss | (54,211) | (84,747) | (36%) | - R&D expenses for Q2 2025 decreased by **$1.5 million** year-over-year, primarily due to a **$2.6 million** reduction in personnel expenses, partially offset by a **$1.6 million** increase in clinical development costs for the EMP-01 program[358](index=358&type=chunk)[360](index=360&type=chunk) - G&A expenses for Q2 2025 increased by **$1.5 million** year-over-year, driven by a **$4.3 million** increase in legal and professional fees related to the Beckley Psytech transaction and redomiciliation[365](index=365&type=chunk) [Liquidity and Capital Resources](index=92&type=section&id=Liquidity%20and%20Capital%20Resources) - As of June 30, 2025, the company had cash, cash equivalents, and short-term securities totaling **$95.9 million**[434](index=434&type=chunk) - Management believes the current cash position is sufficient to fund operations into the second half of 2027[434](index=434&type=chunk) - Net cash used in operating activities for the first six months of 2025 was **$31.9 million**, a decrease from **$38.8 million** in the same period of 2024[440](index=440&type=chunk)[441](index=441&type=chunk)[442](index=442&type=chunk) - Net cash provided by financing activities was **$67.3 million** for the first six months of 2025, primarily from equity offerings, compared to **$0.3 million** in the prior-year period[440](index=440&type=chunk)[445](index=445&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=101&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company's market risks include interest rate sensitivity and foreign currency exchange risk, neither of which is expected to materially impact financial statements - The company's main market risks are interest rate sensitivity on its cash and investments, and foreign currency exchange risk from its international operations[461](index=461&type=chunk) - Due to the nature of its cash and investment portfolio, a hypothetical 100 basis point change in interest rates is not expected to materially affect their fair value[462](index=462&type=chunk) - A hypothetical 10% change in the U.S. dollar's value relative to other currencies would not have had a material effect on the consolidated financial statements for the periods presented[466](index=466&type=chunk) [Controls and Procedures](index=102&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded disclosure controls and procedures were effective as of June 30, 2025, with no material changes to internal control over financial reporting - Management, including the CEO and CFO, concluded that the company's disclosure controls and procedures were effective as of June 30, 2025[468](index=468&type=chunk) - There were no material changes in the company's internal control over financial reporting during the fiscal quarter ended June 30, 2025[469](index=469&type=chunk) PART II. OTHER INFORMATION [Legal Proceedings](index=103&type=section&id=Item%201.%20Legal%20Proceedings) The company is not currently involved in any legal proceedings expected to have a material adverse effect on its financial condition - The company is not currently involved in any legal proceedings that are expected to have a material adverse effect on its business or financial condition[470](index=470&type=chunk) [Risk Factors](index=104&type=section&id=Item%201A.%20Risk%20Factors) New risk factors include those related to the Beckley Psytech acquisition and corporate redomiciliation, such as transaction completion and integration challenges - New risks have been introduced related to the strategic combination with Beckley Psytech, including potential failure to complete the deal, reduced ownership for existing atai shareholders, and challenges in realizing anticipated benefits[472](index=472&type=chunk)[473](index=473&type=chunk)[478](index=478&type=chunk) - The company highlights risks associated with its planned redomiciliation to Delaware, such as the possibility that the expected benefits may not be realized or that the process could be delayed or abandoned[481](index=481&type=chunk)[482](index=482&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=106&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The company reported no unregistered sales of equity securities during the period - The company reported no unregistered sales of equity securities for the period[485](index=485&type=chunk) [Other Information](index=106&type=section&id=Item%205.%20Other%20Information) Disclosures include a $10.0 million unsecured promissory note issued to Beckley Psytech and confirmation of no Rule 10b5-1 trading plan changes - On August 13, 2025, the company issued a **$10.0 million** unsecured promissory note to Beckley Psytech to fund product development milestones, bearing interest at 12% per annum[487](index=487&type=chunk)[488](index=488&type=chunk) - No director or officer adopted or terminated a Rule 10b5-1 trading arrangement during the six months ended June 30, 2025[491](index=491&type=chunk) [Exhibits](index=107&type=section&id=Item%206.%20Exhibits) This section lists all exhibits filed with the Form 10-Q, including agreements for the Beckley Psytech transaction and PIPE financings - Key exhibits filed include the Share Purchase Agreement with Beckley Psytech, various subscription and voting agreements, and the Senior Promissory Note issued to Beckley Psytech[492](index=492&type=chunk)[493](index=493&type=chunk)

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

[Management Commentary](index=1&type=section&id=Management%20Commentary) Management highlights the transformative Beckley Psytech combination, solidifying atai's leadership in psychedelic mental health and advancing its clinical pipeline with strong investor confidence - The planned strategic combination with Beckley Psytech is expected to establish atai as a **global leader** in psychedelic mental health[3](index=3&type=chunk) - The combination adds **BPL-003**, a late-stage, clinically-validated asset for treatment-resistant depression (TRD), to atai's wholly owned pipeline[3](index=3&type=chunk) - Recent fundraising efforts in 2025 totaled nearly **$140 million**, reflecting strong investor confidence in the company's strategy[3](index=3&type=chunk) [Key Highlights](index=1&type=section&id=Key%20Highlights) Positive topline data for BPL-003 in TRD demonstrated rapid, durable effects, with cash expected to fund operations into H2 2027, and key milestones anticipated in Q3 2025 - Positive topline data from the **Phase 2b trial of BPL-003** in TRD met primary and key secondary endpoints, showing single-dose effects for up to **8 weeks**[4](index=4&type=chunk) - Topline data from the eight-week open-label extension of the BPL-003 Phase 2b trial is expected in **Q3 2025**[4](index=4&type=chunk) - The company's cash, securities, and other assets are expected to fund combined operations into the **second half of 2027**[4](index=4&type=chunk) [Recent Clinical Highlights and Upcoming Milestones](index=2&type=section&id=Recent%20Clinical%20Highlights%20and%20Upcoming%20Milestones) Updates on key clinical programs include positive BPL-003 Phase 2b results, VLS-01 data delay to H2 2026, ongoing EMP-01 enrollment, and Inidascamine's Phase 2b trial not meeting its primary endpoint [BPL-003 (Intranasal Mebufotenin)](index=2&type=section&id=BPL-003) BPL-003's Phase 2b study in TRD met all endpoints, showing rapid, durable antidepressant effects for up to 8 weeks, with the 8 mg dose selected for Phase 3 - The Phase 2b study met its primary endpoint, demonstrating rapid and durable antidepressant effects for up to **8 weeks** with a single dose[5](index=5&type=chunk) - BPL-003 was generally well-tolerated, with **99%** of treatment-emergent adverse events being mild or moderate, and no drug-related serious adverse events[5](index=5&type=chunk) - The **8 mg dose** has been selected for Phase 3 advancement, with an End-of-Phase 2 meeting request planned for **Q3 2025**[5](index=5&type=chunk) [VLS-01 (Buccal Film DMT)](index=2&type=section&id=VLS-01) Topline data for VLS-01 in TRD is delayed to H2 2026 due to slower site activation and patient recruitment in its Phase 2 trial - Topline data from the Phase 2 trial of VLS-01 in TRD patients is now anticipated in the **second half of 2026**[5](index=5&type=chunk) - The delay is attributed to slower-than-anticipated site activation and patient recruitment[5](index=5&type=chunk) [EMP-01 (Oral R-MDMA)](index=2&type=section&id=EMP-01) Enrollment continues for the Phase 2 study of EMP-01 for social anxiety disorder, with topline data expected in Q1 2026 - Patient enrollment continues in the Phase 2 study of EMP-01 for social anxiety disorder (SAD)[5](index=5&type=chunk) - Topline data from the Phase 2 study are anticipated in the **first quarter of 2026**[5](index=5&type=chunk) [Inidascamine (RL-007)](index=3&type=section&id=Inidascamine) Inidascamine's Phase 2b trial for CIAS did not meet its primary endpoint, leading atai to reallocate resources to its wholly owned psychedelic programs - The Phase 2b trial of inidascamine for CIAS did not meet its primary endpoint with statistical significance[10](index=10&type=chunk) - atai plans to allocate resources to its wholly owned pipeline of psychedelic product candidates focused on affective disorders[10](index=10&type=chunk) [Novel 5-HT2A Receptor Agonists](index=2&type=section&id=Novel%205-HT2A%20Receptor%20Agonists) Novel 5-HT2A receptor agonists with non-hallucinogenic potential in rodent studies are undergoing further optimization and evaluation for therapeutic use - Discovered novel **5-HT2A receptor agonists** that maintain non-hallucinogenic potential in rodent drug discrimination studies[6](index=6&type=chunk) [Corporate Updates](index=3&type=section&id=Corporate%20Updates) atai is advancing its strategic combination with Beckley Psytech for Q4 2025 shareholder approval and initiating US redomiciliation for structural and operational efficiencies - The planned strategic combination with Beckley Psytech is expected to proceed to shareholder approval in **Q4 2025**[10](index=10&type=chunk) - The company has initiated the process to move its corporate domicile to the US for structural simplification and operational efficiencies[10](index=10&type=chunk) [Consolidated Financial Results](index=3&type=section&id=Consolidated%20Financial%20Results) Q2 2025 net loss significantly narrowed to $27.7 million, cash increased to $95.9 million, R&D expenses decreased, and G&A expenses rose due to strategic transactions [Financial Position and Liquidity](index=3&type=section&id=Financial%20Position%20and%20Liquidity) As of June 30, 2025, cash and equivalents totaled $95.9 million, an increase driven by $89.2 million in equity issuances, funding operations into H2 2027 Cash, Cash Equivalents, and Short-Term Securities | Metric | June 30, 2025 (USD) | December 31, 2024 (USD) | | :--- | :--- | :--- | | Cash, cash equivalents and short-term securities | $95.9 million | $72.3 million | - The **$23.6 million** increase in cash is primarily due to **$89.2 million** in net proceeds from equity issuances, offset by cash used in operations and debt payoff[7](index=7&type=chunk) - The company's cash runway is expected to fund operations for the combined company into the **second half of 2027**[7](index=7&type=chunk) [Operating Expenses and Net Loss](index=3&type=section&id=Operating%20Expenses%20and%20Net%20Loss) Q2 2025 saw R&D expenses decrease to $11.1 million, G&A expenses increase to $14.9 million, and net loss narrow significantly to $27.7 million Operating Expenses and Net Loss (Q2) | Expense Category | 2025 (Millions USD) | 2024 (Millions USD) | Change (Millions USD) | | :--- | :--- | :--- | :--- | | R&D Expenses | $11.1 | $12.6 | ($1.5) | | G&A Expenses | $14.9 | $13.4 | +$1.5 | | Net Loss | ($27.7) | ($57.3) | $29.6 | - The decrease in R&D expenses was primarily due to lower personnel-related expenses and consulting services[8](index=8&type=chunk) - The increase in G&A expenses was largely due to legal and professional service costs related to the planned Beckley Psytech combination and US redomiciliation[9](index=9&type=chunk) [Financial Statements](index=6&type=section&id=Financial%20Statements) Condensed consolidated financial statements detail a Q2 2025 net loss of $27.7 million, with total assets of $189.2 million and stockholders' equity of $143.9 million [Condensed Consolidated Statements of Operations](index=6&type=section&id=CONDENSED%20CONSOLIDATED%20STATEMENTS%20OF%20OPERATIONS) Q2 2025 statements show revenue of $0.7 million, total operating expenses of $26.0 million, and a net loss of $27.7 million, or ($0.14) per share Condensed Consolidated Statements of Operations (Three Months Ended June 30) | Metric | 2025 (unaudited) | 2024 | | :--- | :--- | :--- | | Revenue (Thousands USD) | $719 | $273 | | Total operating expenses (Thousands USD) | $25,992 | $26,002 | | Loss from operations (Thousands USD) | ($25,273) | ($25,729) | | Net loss attributable to stockholders (Thousands USD) | ($27,729) | ($57,312) | | Net loss per share — basic and diluted (USD) | ($0.14) | ($0.36) | [Condensed Consolidated Balance Sheet](index=7&type=section&id=CONDENSED%20CONSOLIDATED%20BALANCE%20SHEET) As of June 30, 2025, the balance sheet reports total assets of $189.2 million, total liabilities of $45.3 million, and stockholders' equity of $143.9 million Condensed Consolidated Balance Sheet (Thousands USD) | Metric | June 30, 2025 (unaudited) | December 31, 2024 | | :--- | :--- | :--- | | Cash and cash equivalents | $61,940 | $17,505 | | Total assets | $189,204 | $159,387 | | Total liabilities | $45,279 | $42,833 | | Total stockholders' equity | $143,925 | $116,554 | [Legal Disclaimers and Forward-Looking Statements](index=4&type=section&id=Legal%20Disclaimers) This section outlines forward-looking statements regarding business strategy, clinical development, the Beckley Psytech transaction, and financial projections, all subject to significant risks and uncertainties - The press release includes forward-looking statements regarding business strategy, product candidate development, the proposed transaction with Beckley Psytech, and cash runway[13](index=13&type=chunk) - These statements involve risks and uncertainties, including the possibility that proposed transactions may not be completed or their anticipated benefits realized[14](index=14&type=chunk) - Investors are urged to read the S-4 Registration Statement and Proxy Statement, when available, for important information about the proposed transactions[16](index=16&type=chunk)

Planned strategic combination with Beckley Psytech expected to solidify position as global leader in transformative, psychedelic-based mental health therapies with a short time in-clinic NEW YORK and AMSTERDAM, Aug. 14, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) ("atai" or "Company"), a clinical-stage biopharmaceutical company on a mission to develop highly effective mental health treatments to transform patient outcomes, today announced second quarter 2025 financial results and provided cor ...

Group 1 - Atai Life Sciences (NASDAQ: ATAI) reported results from its phase 2b study of inidascamine for treating cognitive impairment associated with schizophrenia, indicating a negative outcome [2] - The company is part of the Biotech Analysis Central service, which provides extensive analysis and a model portfolio of biotech stocks [2] Group 2 - The article emphasizes the importance of informed decision-making for healthcare investors through detailed analysis and news reports [2]

Core Insights - Recognify Life Sciences announced that its Phase 2b clinical trial for inidascamine did not meet its primary endpoint for cognitive improvement in patients with cognitive impairment associated with schizophrenia [1][2] - Despite not achieving statistical significance, inidascamine showed consistent numerical improvements across various cognitive measures, including Symbol Coding and Verbal Learning [2][4] - The drug demonstrated a favorable safety profile, with no significant side effects commonly associated with schizophrenia treatments [3][4] Company Overview - Recognify Life Sciences is a clinical-stage biotech company focused on developing pro-cognitive treatments for mental health and neurodegenerative disorders [10] - The company is a strategic investment of atai Life Sciences, which is also involved in developing psychedelic-based therapies for mental health [11] Clinical Trial Details - The Phase 2b trial enrolled 242 patients across the United States and Europe, evaluating the efficacy, safety, and tolerability of inidascamine over a six-week period [4] - The study's primary endpoint was based on the MCCB neurocognitive composite score, which did not show statistical significance, but secondary and exploratory endpoints are still under analysis [2][4] Future Directions - Recognify Life Sciences plans to present additional results from the study at scientific meetings and will evaluate strategic options for inidascamine based on the complete data set [5][6] - The ongoing analysis aims to identify potential responder populations and mechanistic insights that could guide future development [4][5] Industry Context - Cognitive impairment associated with schizophrenia affects approximately 80% of patients, representing a significant unmet clinical need, as there are currently no effective pharmaceutical treatments approved for this condition [9] - The global prevalence of schizophrenia is over 21 million, with around 2.4 million cases in the United States [9]

Core Viewpoint - atai Life Sciences N.V. (ATAI) has been upgraded to a Zacks Rank 1 (Strong Buy) due to an upward trend in earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Movement - The Zacks rating system emphasizes the importance of changing earnings estimates, which are closely correlated with near-term stock price movements [4][6]. - Rising earnings estimates for atai Life Sciences indicate an improvement in the company's underlying business, likely leading to an increase in stock price [5][10]. Zacks Rating System - The Zacks Rank stock-rating system categorizes stocks into five groups based on earnings estimates, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988 [7][9]. - Only the top 5% of Zacks-covered stocks receive a "Strong Buy" rating, indicating superior earnings estimate revisions [9][10]. Recent Earnings Estimate Revisions - For the fiscal year ending December 2025, atai Life Sciences is expected to earn -$0.54 per share, unchanged from the previous year [8]. - Over the past three months, the Zacks Consensus Estimate for atai Life Sciences has increased by 27.9% [8].

Group 1 - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The news team covers medium and small-cap markets, as well as blue-chip companies, commodities, and broader investment stories [3] - Proactive focuses on sectors such as biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Group 2 - Proactive is committed to adopting technology to enhance workflows and content production [4] - The company utilizes automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [5]